Australia Health

Entropy Neurodynamics (ASX:ENP) has reported Phase 2a clinical trial results showing that TRP-8802, an oral psilocybin therapy.

Singular Health (ASX:SHG) has announced that the US Food and Drug Administration has granted 510(k) clearance for 3DICOM MD Cloud, the company's cloud-based evolution of its FDA-cleared 3DICOM MD software.

Enlitic (ASX:ENL) has completed technical validation of its Ensight medical imaging data standardisation platform on Oracle Cloud Infrastructure, leveraging AMD EPYC processors.

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced encouraging results from its Special Access Program for patients with fistulising Crohn's disease.

LTR Pharma (ASX:LTP) has commenced patient recruitment for its Phase 2 pharmacokinetic study of SPONTAN, the company's rapid-acting intranasal spray for the treatment of erectile dysfunction, in Australia.

Tetratherix (ASX:TTX) has announced a major clinical milestone for its TetraDerm product, with the completion of the second safety review of the trial’s second cohort.

ReNerve (ASX:RNV), an Australian medical device innovator specialising in peripheral nerve injury solutions, has secured broader listing approval for its NervAlign Nerve Cuff in Hong Kong.

WA medicinal cannabis manufacturer Cannaponics is eyeing an Australian Securities Exchange listing in the second half of this year.

Imricor Medical Systems (ASX:IMR) announced that the US Food and Drug Administration has granted 510(k) clearance for its Vision-MR Diagnostic Catheter.

Nova Eye Medical (ASX:EYE) has reported a record sales performance for the December 2025 quarter, with global revenue reaching US$6.1 million.

CLINUVEL Pharmaceuticals (ASX:CUV) has begun dosing in a preclinical study of its controlled-release injectable peptide platform, VLRX-L.

Radiopharm Theranostics (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, a joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%.